Chu T M, Lin T H, Kawinski E
Department of Diagnostic Immunology Research and Biochemistry, Roswell Park Cancer Institute, New York State Department of Health, Buffalo 14263.
Biochem Biophys Res Commun. 1994 Aug 30;203(1):506-12. doi: 10.1006/bbrc.1994.2211.
Multidrug resistance (MDR) is a unique phenomenon in cancer patients and is commonly associated with an overexpression of the human MDR gene mdr1, which encodes an energy-dependent Mr 180 kDa membrane bound protein, known as P-glycoprotein. P-glycoprotein serves as a membrane efflux to pump the drugs out of the cancer cells. Western blot analysis, using a newly generated monoclonal antibody F4 which recognizes specifically an extracellular epitope of human MDR1 P-glycoprotein, reveals that soluble P-glycoprotein is detected in the cultured media of viable adriamycin-resistant human ovarian carcinoma 2780AD cells, whereas those of the drug-sensitive parent A2780 cells contain no detectable level of soluble P-glycoprotein. Soluble P-glycoprotein also is detected in extracellular fluids of cancer patients, such as malignant ascites and serum, and is not detectable in serum samples of normal healthy individuals. The Mr of soluble P-glycoprotein is the same as that of membrane bound P-glycoprotein. The presence of soluble P-glycoprotein in extracellular fluids may provide the basis for its use as a quantitative parameter of MDR and as a means to lessen or reverse MDR.
多药耐药性(MDR)是癌症患者中一种独特的现象,通常与人类MDR基因mdr1的过表达相关,该基因编码一种分子量为180 kDa的能量依赖性膜结合蛋白,即P-糖蛋白。P-糖蛋白作为一种膜转运蛋白,将药物泵出癌细胞。使用新产生的特异性识别人类MDR1 P-糖蛋白细胞外表位的单克隆抗体F4进行蛋白质印迹分析表明,在存活的阿霉素耐药性人卵巢癌2780AD细胞的培养基中可检测到可溶性P-糖蛋白,而药物敏感的亲本A2780细胞的培养基中未检测到可溶性P-糖蛋白。在癌症患者的细胞外液中,如恶性腹水和血清中,也可检测到可溶性P-糖蛋白,而在正常健康个体的血清样本中未检测到。可溶性P-糖蛋白的分子量与膜结合P-糖蛋白相同。细胞外液中可溶性P-糖蛋白的存在可能为其作为MDR的定量参数以及减轻或逆转MDR的手段提供依据。